Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Medulloblastoma

WNT, SHH, Group 3 and Group 4 disease, and relapse after craniospinal radiotherapy.

Live from ClinicalTrials.gov + PubMed, fetched 2026-11-12 10:56 UTC. Every row links to its source record.

Principal investigators and study chairs named on the registry for medulloblastoma, ranked by a published score: 3 per Phase 2+ trial they lead, 1 per other trial role, 2 per oral or late-breaking talk and 0.5 per poster in our verified 2026 meeting rows, each halved every 24 months. Paper authorship is not scored yet. PubMed counts are author name plus indication, for the top 12; names are as the registry spells them, so a common name can pool several people. Open a row for their trials and links to their papers.

Eric M Thompson

Washington University School of Medicine

score 4.3

21 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 4.3 = 4.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

Maryam Fouladi

Nationwide Children's Hospital

score 4.3

50 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 4.3 = 4.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

Girish Dhall

Children's Hospital of Alabama

score 3

24 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph3NCT07291102 · Nationwide Children's Hospital · Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

Yang Li

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

score 2.9

131 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT07856069 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma

Jonathan Metts

Moffitt Cancer Center

score 2.3

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT06701812 · H. Lee Moffitt Cancer Center and Research Institute · Digoxin Medulloblastoma Study

Laura Metrock

University of Alabama at Birmingham Children's of Alabama

score 2.3

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT06701812 · H. Lee Moffitt Cancer Center and Research Institute · Digoxin Medulloblastoma Study

Daniel Landi

Duke Cancer Center

score 1.3

5 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05096481 · Nationwide Children's Hospital · PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Ralph Salloum

Dana-Farber Cancer Institute

score 1.1

16 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.1 = 1.1 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

Kevin A Camphausen

National Cancer Institute (NCI)

score 1.1

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1.1 = 1.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06161519 · National Cancer Institute (NCI) · PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Elias Sayour

University of Florida

score 1

2 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 2 trials are Phase 2+.

Aleksander Wiśniewski

The Children's Memorial Health Institute

score 0.9

0 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07865130 · Bożenna Dembowska Bagińska · Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

Bożenna Dembowska-Bagińska

The Children's Memorial Health Institute

score 0.9

12 papers

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07865130 · Bożenna Dembowska Bagińska · Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

Magdalena Kozłowska

The Children's Memorial Health Institute

score 0.9

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07865130 · Bożenna Dembowska Bagińska · Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

Sameer Farouk Sait

Memorial Sloan Kettering Cancer Center

score 0.9

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07698899 · Memorial Sloan Kettering Cancer Center · A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

Susan Chi

Dana-Farber Cancer Institute

score 0.9

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07390539 · Robbie Majzner · B7-H3.CD28Z.CART in CNS Neoplasms

Aditi Bagchi

St. Jude Children's Research Hospital

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05535166 · St. Jude Children's Research Hospital · Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Giles W. Robinson

St. Jude Children's Research Hospital

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05535166 · St. Jude Children's Research Hospital · Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Margot Lazow

Nationwide Children's Hospital

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT05278208 · Nationwide Children's Hospital · Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Sabine Mueller

University of California, San Francisco

score 0.8

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07492316 · University of Florida · RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Asim Bag

St. Jude Children's Research Hospital

score 0.7

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT05128903 · St. Jude Children's Research Hospital · Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study

Eric Bouffet

The Hospital for Sick Children

score 0.7

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph3NCT05230758 · Donald Mabbott · Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour

Peter Hau

EORTC study coordinator

score 0.7

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04402073 · European Organisation for Research and Treatment of Cancer - EORTC · Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Katherine Ryan

Stanford University

score 0.7

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT07087002 · Stanford University · GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Duane Mitchell

University of Florida

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

Matthias Karajannis

Memorial Sloan Kettering Cancer Center

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04743661 · Pediatric Brain Tumor Consortium · 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

John Ligon

University of Florida

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06514898 · University of Florida · Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Tobey MacDonald

Emory University

score 0.6

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06624371 · Emory University · Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

Marta Osuna Marco

HM Monteprincipe

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph1/Ph2NCT06607692 · Fundación de investigación HM · Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Brian Rood

Children's National Research Institute

score 0.5

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06193759 · Children's National Research Institute · Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Andrea T Franson

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04320888 · National Cancer Institute (NCI) · Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Christine A Pratilas

Children's Oncology Group

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04284774 · National Cancer Institute (NCI) · Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Michael A Huang

Beat Childhood Cancer

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04696029 · Giselle Sholler · DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Jeffrey M. Treiber

The University of Texas Health Science Center, Houston

score 0.4

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0 leading Phase 2+ trials + 0.4 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT06466798 · Jeffrey Treiber · Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Elizabeth D Alva

Children's Oncology Group

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04195555 · National Cancer Institute (NCI) · Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Theodore S Johnson

Augusta University

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT04049669 · Theodore S. Johnson · Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Christopher DeRenzo

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Giedre Krenciute

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Kelsey Bertrand

St. Jude Children's Research Hospital

score 0.3

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Ph1NCT05835687 · St. Jude Children's Research Hospital · Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Alice Lee

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03210714 · National Cancer Institute (NCI) · Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Kieuhoa T Vo

Children's Oncology Group

score 0.2

–

Profile: all trials, NIH grants and most cited papers →Papers in medulloblastoma (PubMed)Trial papers only All registered trials naming them (ClinicalTrials.gov)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Ph2NCT03698994 · National Cancer Institute (NCI) · Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)